ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination

BOSTON, Jan. 14, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ: ENVI) ("ENVI"), a publicly-traded special purpose acquisition company, announced today that ENVI's definitive proxy statement/prospectus (the "Proxy Statement") relating to the previously announced business combination with GreenLight Biosciences, Inc. ("GreenLight"), a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, has been filed with the U.S. Securities and Exchange Commission (the "SEC") on January 13, 2022.

Read more at prnewswire.com